Long-term costs and clinical outcomes associated with metformin-glibenclamide combination tablets (Glucovance®) in patients with type 2 diabetes sub-optimally controlled by metformin: a modelling study in the French setting

Abstract

Objectives

Most patients eventually become hyperglycaemic on metformin monotherapy. We modelled clinical and economic consequences for such patients of switching to a single-tablet metformin-glibenclamide combination (Glucovance®) or glibenclamide, or increasing metformin dosage.

Methods

A validated computer simulation model of diabetes projected long-term clinical and cost outcomes for the French setting, using data from a 16-week randomised controlled trial.

Results

Compared with metformin, Glucovance® 500/2.5 mg or 500/5 mg was associated with increased quality-adjusted life expectancy (0.45 and 0.27 quality-adjusted life-years [QALYs] respectively; base case analysis), reduced direct medical costs (by 3,331 and 2,026) and fewer diabetes-related complications. Compared with glibenclamide, Glucovance® 500/5 mg increased quality-adjusted life expectancy by 0.28 QALYs and reduced direct medical costs by 1,793.

Conclusions

From a third-party healthcare payer perspective in France, Glucovance® represents a dominant treatment option versus metformin or glibenclamide for patients sub-optimally controlled on metformin monotherapy.

Keywords

cost-effectiveness glibenclamide Glucovance®metformin oral antidiabetic combination therapy type 2 diabetes.

References

UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.

Clinical Guidelines Task Force, International Diabetes Federation. 2005 Global Guideline for Type 2 Diabetes . Available at www.idf.org

Nathan DM , Buse JB , Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006;49:1711-21.

Turner RC , Cull CA , Frighi V. , Holman RR Glycaemic control with diet, sulphonylurea, metformin or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281:2005-12.

Scarpello JHB. Optimal dosing strategies for maximising the clinical response to metformin in type 2 diabetes. Br J Diabetes Vasc Dis 2001;1:28-36.

Marre M. , Howlett H. , Lehert P. , Allavoine T. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance®) in Type 2 diabetic patients inadequately controlled on metformin . Diabet Med 2002;19:673-80.

Palmer AJ , Roze S. , Valentine WJ et al. The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Cost-effectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making. Curr Med Res Opin 2004;20(8

suppl):5-26. 8. Stratton IM , Adler AI , Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J 2000;321:405-12.

Palmer AJ , Roze S. , Valentine W. et al. P Validation of the CORE Diabetes Model against Epidemiological and Clinical Studies. Curr Med Res Opin 2004 ;20(suppl 1):S27-S40.

10.

Detournay B. , Cros S. , Charbonnel B. et al. Managing type 2 diabetes in France: the ECODIA survey. Diabetes Metab 2000;26:363-9.

11.

Fagnani F. , Souchet T. , Labed D. Incidence, management and cost of cardio-vascular and renal complications in French type 2 diabetic patients in 2001 [Abstract]. Value Health 2003;5:206.

12.

Montagne O. , Chaix C. , Harf A. , Castaigne A. , Durand-Zaleski I. Costs for acute myocardial infarction in a tertiary care centre and nationwide in France. Pharmacoeconomics 2000;17:603-09.

13.

Levy P. , Lechat P. , Leizorovicz A. , Levy E. A cost-minimization of heart failure therapy with bisoprolol in the French setting: an analysis from CIBIS trial data. Cardiac Insufficiency Bisoprolol Study. Cardiovasc Drugs Ther 1998;12:301-05.

14.

LePen C. , Lilliu H. , Keller T. , Fiessinger S. The economics of TRACE. A cost-effectiveness analysis of trandolapril in postinfarction patients with left ventricular dysfunction. Pharmacoeconomics 1998;14:49-58.

15.

Mullins CD , Sikirica M. , Seneviratne V. , Ahn J. , Akhras KS Comparisons of hypertension-related costs from multinational clinical studies . Pharmacoeconomics 2004;22:1001-14.

16.

Levy E. , Gabriel S. , Dinet J. The comparative medical costs of atherothrombotic disease in European countries . Pharmacoeconomics 2003;21:651-9.

17.

Palmer AJ , Annemans L. , Roze S. , Lamotte M. , Rodby RA , Cordonnier D. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003;18:2059-66.

18.

Grueger J. , O'Brien B. , Caro J. , Everhard F. The lifetime direct medical costs of managing diabetes and its complications in France [Abstract]. Value Health 2001;4:504-05.

19.

Bonastre J. , Le Pen C. , Soubrane G. , Quentel G. The burden of age-related macular degeneration: results of a cohort study in two French referral centres. Pharmacoeconomics 2003;21:181-90.

20.

Nghiem-Buffet MH , de Pouvourville G. , Renard G. , Ullern M. , Boureau C. , Chaine G. [Cost of managing cataracts. Evaluation of traditional hospitalization and ambulatory surgery] . Presse Med 2001;30:1924-6.

21.

Ghatnekar O. , Persson U. , Willis M. , Odegaard K. Cost effectiveness of Becaplermin in the treatment of diabetic foot ulcers in four European countries . Pharmacoeconomics 2001;19:767-78.

22.

Cnamts. La Classification Commune des Actes Médicaux (CCAM) . 2002.

23.

24.

Tarn T. , Smith M. Pharmacoeconomic guidelines around the world. ISPOR Connections 2004;10:5-15.

25.

Briggs AH , Wonderling DE , Mooney CZ Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40.

26.

Garber AJ , Duncan TG , Goodman AM , Mills DJ , Rohlf JL Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997;103:491-7.

27.

Charpentier G. , Genes N. , Vaur L. et al. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes: a nationwide French survey . Diabetes Metab 2003;29:152-8.

28.

Fox KM , Gerber Pharmd RA , Bolinder B. , Chen J. , Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388-95.

29.

Del Prato S. , Felton AM , Munro N. , Nesto R. , Zimmet P. , Zinman B. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract 2005;59:1345-55.

30.

Veehof L. , Stewart R. , Haaijer-Ruskamp F. , Jong BM The development of polypharmacy. A longitudinal study. Fam Pract 2000;17:261-7.

31.

Rubin RR Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus . Am J Med 2005;118 (suppl 5A):27S-34S.

32.

Dailey G. , Kim MS , Lian JF Patient compliance and persistence with anti-hyperglycaemic therapy: evaluation of a population of type 2 diabetic patients. J Int Med Res 2002;30:71-9.

33.

Melikian C. , White TJ , Vanderplas A. , Derji CM , Chang E. Adherence to oral antidiabetic therapy in a managed care organisation: a comparison of monotherapy, combination therapy and fixed-dose combination therapy. Clin Ther 2002;24:460-7.

34.

Duckworth W. , Marcelli M. , Padden M. et al. Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets. J Manag Care Pharm 2003;9:256-62.

35.

Kahn SE , Haffner SM , Heise MA et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43.